FDA Grants Fast Track Designation to NS-065/NCNP-01 for the Treatment of Duchenne Muscular Dystrophy.
http://www.nippon-shinyaku.co.jp/english/company_profile/news.php?id=3113
- Home
-
Products and Applications
-
Morpholino Antisense Oligos
- Why Morpholinos?
- Optimal Target Choice
- Methods/Protocols
- Morpholino Products and Properties
- End Modifications and Controls
- Blocking miRNAs
- Blocking Localization Elements of mRNA
- Modify poly-A Tailing
- Other targets: ncRNA, repeat elements, etc.
- External guides for use with RNase P
- Diagnostics
- Uses for Pretargeting & Crosslinking
- Therapeutics
- Bacteria Applications
- Protist Applications
- Insect Applications
-
Morpholino Antisense Oligos
- Ordering
- Customer Support
- Morpholino Publications Database
- FAQ
- About Us
- Contact Us
Add new comment